TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 40 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.~* Diagnosis of type 2 diabetes.~* Established cardiovascular disease with at least one of the following: coronary artery disease, cerebrovascular disease, or peripheral arterial disease.~* HbA1c \>7.0% (53 mmol/mol) (based on the most recent documented laboratory measurement within 6 months).~* Able and willing to provide informed consent.~Exclusion Criteria:~* Severely reduced kidney function: eGFR \<30 ml/min/1.73 m\^2 (based on the last measured and documented laboratory measurement within 6 months) or renal replacement therapy.~* Use of a GLP-1 receptor agonist at Screening.~* Severe gastroparesis~* History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study.~* Personal or family history of medullary carcinoma of the thyroid or subject with multiple endocrine neoplasia type 2 (MEN-2). Personal history of pancreatic neuroendocrine tumours.~* Medical history which might limit the subject's ability to take trial treatments for the duration of the study or to otherwise complete the study.~* Breastfeeding, pregnancy, or planning a pregnancy during the course of the study. Note: a pregnancy test will be performed on all women of child bearing potential prior to study entry.~* Known allergy to any GLP-1 receptor agonist or excipients of albiglutide.~* Use of another investigational product within 30 days or according to local regulations, or currently enrolled in a study of an investigational device.~* Any other reason the investigator deems the subject to be unsuitable for the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albiglutide (Type: EXPERIMENTAL): Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propionyl-L-Carnitine in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have read the Information for the Patient and signed the Informed Consent Form.~* Age comprised between 18 and 75 included.~* If female, not pregnant or nursing.~* For women of childbearing potential, willingness to avoid a pregnancy during the treatment period and for at least 1 month from the last dose of drug.~* Availability of a pancolonoscopy and histology both confirming the diagnosis of active ulcerative colitis.~* Disease Activity Index comprised between 3 and 10, inclusive, (mild to moderate ulcerative colitis).~* On one of the following treatments for ulcerative colitis prior to baseline visit:~  1. Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or sulfasalazine therapy for greater than or equal to 4 weeks prior to baseline assessments.~ 2. Stable background mercaptopurine or azathioprine for greater than or equal to 12 weeks prior to baseline assessments.~Exclusion Criteria:~* First diagnosis of ulcerative colitis.~* Crohn's disease.~* Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.~* Use of antibiotics in the last 10 days preceding the screening.~* Use of NSAID's in the last 10 days preceding the screening.~* Use of probiotics in the last 10 days preceding the screening~* Positive stool culture (when performed, according to Investigator's judgment, to assess possible parasitologic infection(s)).~* Significantly impaired liver, renal, pulmonary or cardiovascular function.~* History of colon resection.~* Diverticulitis.~* Diagnosis of proctitis~* Stable rectally administered therapy in the last 10 days.~* Active or chronic infection(s).~* Simultaneous participation in another clinical trial, or participation in any clinical trial involving investigational drugs within 3 months from enrolment into the present study.~* Any physical or psychological condition in a patient that could let the investigator suspect his/her poor compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PLC Colon release tablet 1 g (Type: EXPERIMENTAL): 40 patients each arm
- PLC colon release tablet 2 g (Type: EXPERIMENTAL): 40 patients each arm
- Placebo PLC colon release tablet 2 g (Type: PLACEBO_COMPARATOR): 40 patients each arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Eligibility requirements includes the following criteria:~* Age \>18 years and \< 65~* Performance status \< 3~* Histologically or biologically documented GCTs~* Testicular, abdominal, or mediastinal tumors~* Measurable or evaluable disease~* Life expectancy \> 3 months~* Normal cardiac, liver, and renal function tests~* Absence of infection~* HIV negative test~* Signed informed consent~* All patients had to have been previously treated with at least one line of a cisplatin-containing regimen and were included if they were refractory after one or two line(s) of cisplatin-based CT, or had relapsed after two lines of a cisplatin-based CT~Exclusion Criteria:~* Fireproof diseases (progress unless month with regard to the last cycle of chemotherapy or in the course of chemotherapy)~* Relapses after complete answer obtained by surgery ( sCR )~* Neuropathy of superior rank or = II - renal Function (Office) superior creatinine or = 125 mmol/l and/or clearance of the creatinine subordinate or = II 60ml / mn~* Antecedents of congestive even compensated cardiac insufficiency~* Hurts of growing teratoma that is measurable hurts increasing by size (cutting) in the absence of rise of marker pens~* Extensive chemotherapy with support of haematopoietic stem cells. NB: A previous preventive irradiation under diaphragmatitis for a seminoma stage I (dose from 24 to 30 Gy in classic spreading) does not establish one against formal indication. However, an estimation clarifies capacities of the haematopoietic marrow is recommended with observation of the evolution of the NFP in the course of chemotherapy and quantification of cells CD 34 + in the peripheral blood. It's the same of the case where a chemotherapy by carboplatine was realized

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec).~* Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for ≥ 3 months prior to the screening visit.~* HIV ribonucleic acid (RNA) \< 50 copies/mL at the screening visit.~* Currently on a stable regimen for ≥ 3 months preceding the screening visit with documented plasma HIV-1 RNA \< 50 copies/mL for ≥ 3 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).~* Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), DTG, ABC or 3TC.~Key Exclusion Criteria:~* Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance.~* Active tuberculosis infection.~* Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).~* Females who are pregnant.~* Females who are breastfeeding.~* Acute hepatitis in the 30 days prior to study entry.~* Chronic Hepatitis B Virus (HBV) infection.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinded Phase: B/F/TAF (Type: EXPERIMENTAL): B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
- Blinded Phase: ABC/DTG/3TC (Type: ACTIVE_COMPARATOR): ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
- Open-Label Phase (Type: EXPERIMENTAL): At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RA Denosumab on Bone Microstructure Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* with a diagnosis of RA according to the 2010 new 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria~* at an age over 18 years old~* have a lumbar spine, or total hip or distal radius T-score lower than -1.5 by DXA~* without severe deformity in metacarpophalangeal (MCP) joints which would influence the longitudinal assessment of HR-pQCT~* consent to receive alendronate if randomized to standard treatment group.~Exclusion Criteria:~* they have previous use of denosumab, teriparatide, alendronate or other anti-resorptive agents;~* they have a history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis or GI ulceration) or have experienced any previous adverse reaction to bisphosphonate therapy;~* they are receiving other bone-active drugs, such as hormonal replacement therapy, thyroxine, thiazide and diuretics;~* they have conditions affecting bone metabolism; contraindications to alendronate and denosumab (uncorrected hypocalcemia);~* they have unexplained hypocalcemia;~* they have severe renal impairment or serum creatinine level of \>200umol/L;~* they are pregnant or breastfeeding;~* they do not understand Chinese or are incompetent in giving consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
- Standard treatment (Type: ACTIVE_COMPARATOR): Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medication Abortion Via Pharmacy Dispensing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Patient Inclusion Criteria:~* Women seeking medication abortion through 70 days gestation~* Eligible for Mifeprex® at a study clinical site~* English or Spanish speaking~* Willing and able to participate in the study, including willing to go to the study pharmacy to obtain mifepristone~Patient Exclusion Criteria:~* Not pregnant~* Not seeking medication abortion~* Under the age of 15~* Contraindications for medication abortion~  * All pharmacists providing services at one of the study pharmacies during the study are eligible for the pharmacist survey and interview.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Medication abortion patients (Type: EXPERIMENTAL): Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
- Pharmacists (Type: OTHER): Pharmacists providing services at one of the study pharmacies during the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female daily smokeless tobacco users aged 18 years and older, who are motivated to stop use of all tobacco products.~* Subjects must be daily users of nicotine containing smokeless tobacco and using smokeless tobacco on at least 8 occasions per day averaged over a week.~* Have used smokeless tobacco for at least 1 year prior to screening with no period of abstinence \>3 months in the past year.~Exclusion Criteria:~* Subjects using nicotine containing products (including smoking tobacco) other than smokeless tobacco for 3 months prior to screening.~* Subjects with exhaled Carbon Monoxide (CO) \>10 ppm at baseline.~* Subjects who have used varenicline, bupropion, or NRT within 3 months of screening.~* Subjects currently or within the past 12 months requiring treatment for depression or have a current or prior history of panic disorder, psychosis, bipolar disorder or any other serious mental illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 1 year and above and neither pregnant nor breast feeding.~* Weight over 10 kg.~* Body temperature ≥37.5°C) or history of fever in the last 24 hours.~* P. falciparum mono-infection.~Exclusion Criteria:~* Evidence of severe illness malaria or danger signs.~* Known allergy to study medications.~* Hemoglobin \<8 g/dl.~* Antimalarials taken within last 2 weeks.~* Blood transfusion within last 90 days and evidence of recent use (within 14 days)of or will be taking other drugs known to cause hemolysis in G6PD deficient subjects.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- artemether-lumefantrine+placebo (Type: ACTIVE_COMPARATOR): In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
- artemether-lumefantrine+primaquine (Type: EXPERIMENTAL): All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* msSBP (mean of 3 systolic blood pressure measurements) must be ≥ 95th percentile for age, gender and height, at Visit 2 (randomization), in study CSPP100A2365~* Must be ≥ 20 kg and ≤ 150 kg at Visit 2 (randomization), in study CSPP100A2365~* Must be able to swallow minitablets (2mm in diameter) administered in soft food~* Successful completion of Phase 1 (dose response phase) and at least 1 week of Phase 2 (placebo withdrawal phase) of the CSPP100A2365 protocol, with no serious drug-related adverse event(s).~Exclusion Criteria:~* Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than oral/topical steroids, for any medical condition~* Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or obstructive valvular disease~* msSBP ≥ 25% above the 95th percentile~* Second or third degree heart block without a pacemaker~* AST/SGOT or ALT/SGPT \>3 times the upper limit of the reference range~* Total bilirubin \> 2 times the upper limit of the reference range~* Creatinine clearance \< 30 mL/min/1.73m² (calculated using Modified Schwartz formula to estimate glomerular filtration rate \[GFR\]), based on the serum creatinine concentration obtained at the screening visit)~* WBC count \< 3000/mm³~* Platelet count \< 100,000/mm³~* Serum potassium \> 5.2 mEq/L~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: EXPERIMENTAL): Patients will receive one of the following doses based on the their weight: Low weight (≥20 to \<50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to \<80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
- Enalapril (Type: ACTIVE_COMPARATOR): Patients will receive one of the following doses based on their weight: Low weight (≥20 to \<50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to \<80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Muslim men and women with type 2 diabetes~* Participants who intend to fast during the month of Ramadan~* Participants who have been on a stable dose of sulfonylurea for at least three months~Exclusion Criteria:~* Participants with type 1 diabetes mellitus~* Pregnant or breast feeding women~* Participants with hypersensitivity or contraindication to dipeptidyl peptidase (DPP-4) treatment~* Participants on insulin~* Participants on any class of oral diabetic therapy other than sulfonylurea or metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
- Sulfonylurea (Type: ACTIVE_COMPARATOR): Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete